Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation in Acute Ischemic Stroke (SeeBCI)

22 settembre 2026 aggiornato da: Shandong Provincial Hospital

Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation Training in Patients With Acute Ischemic Stroke: The SeeBCI Study

This is a single-center, prospective, randomized, sham-controlled pilot clinical study designed to evaluate the efficacy, safety, and feasibility of early non-invasive electroencephalography-based brain-computer interface (EEG-BCI) rehabilitation training in patients with acute ischemic stroke.

Eligible participants are adults aged 18 to 80 years with acute ischemic stroke, unilateral upper extremity motor impairment on the dominant-hand side, a baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score of 10 to 50, and confirmed clinical stability 48 to 72 hours after stroke onset.

Participants will be randomly assigned in a 1:1 ratio to receive either real EEG-BCI training plus standard early rehabilitation or sham BCI training plus standard early rehabilitation. Both groups will receive 10 days of training, with two sessions per day and approximately 30 minutes per session.

The primary outcome is the change in FMA-UE score from baseline to 30 days after randomization. Secondary outcomes include changes in FMA-UE, Action Research Arm Test (ARAT), National Institutes of Health Stroke Scale (NIHSS), Modified Barthel Index (MBI), and modified Rankin Scale (mRS). Safety outcomes include symptomatic intracranial hemorrhage, any intracranial hemorrhage, neurological deterioration, seizures, falls, cardiovascular events, and training-related adverse events.

This pilot study aims to provide preliminary evidence regarding the feasibility, safety, and potential efficacy of early EEG-BCI rehabilitation after acute ischemic stroke and to inform the design of future multicenter randomized controlled trials.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 80 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Age 18 to 80 years.
  2. Diagnosis of acute ischemic stroke.
  3. Stroke onset to randomization within 48 to 72 hours.
  4. Meets predefined clinical stability criteria before randomization.
  5. Unilateral upper extremity motor impairment on the dominant-hand side.
  6. Baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score between 10 and 50.
  7. Pre-stroke modified Rankin Scale (mRS) score ≤2.
  8. Written informed consent obtained from the participant or legally authorized representative.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Real EEG-BCI Training + Standard Early Rehabilitation

Participants will receive real electroencephalography-based brain-computer interface (EEG-BCI) training combined with standard early rehabilitation. The EEG-BCI training uses upper extremity motor imagery or motor attempt tasks with real-time decoding of motor intention and virtual hand feedback. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total).

Non-invasive EEG-based brain-computer interface training combined with standard early rehabilitation. The intervention includes EEG signal acquisition, motor intention decoding, and real-time virtual hand feedback. Participants perform upper extremity motor imagery or motor attempt tasks. Training is delivered twice daily for approximately 30 minutes per session for 10 consecutive days.

Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions.

Comparatore fittizio: Sham BCI Training + Standard Early Rehabilitation

Participants will receive sham BCI training combined with standard early rehabilitation. The sham procedure will match the real EEG-BCI training in appearance, frequency, duration, and workflow, but the feedback will not be generated by real-time EEG-based motor intention decoding. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total).

Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions.

Sham BCI training designed to maintain participant masking. The procedure matches real EEG-BCI training in device setup, training environment, frequency, duration, and workflow, but the feedback is not linked to the participant's real-time EEG motor intention decoding.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score From Baseline to Day 30
Lasso di tempo: Baseline to Day 30 after randomization

The primary outcome is the change in FMA-UE score from baseline (T0) to 30 days after randomization. The FMA-UE evaluates upper extremity motor function after stroke, with scores ranging from 0 to 66. Higher scores indicate better upper extremity motor function. Change score is calculated as the FMA-UE score at Day 30 minus the baseline FMA-UE score.

Baseline to Day 30 after randomization

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score
Lasso di tempo: Baseline, Day 10, Day 30, and Day 90

Upper extremity motor function will be assessed using the FMA-UE. The total score ranges from 0 to 66, with higher scores indicating better motor function.

Baseline, Day 10, Day 30, and Day 90
Action Research Arm Test (ARAT) Score
Lasso di tempo: Baseline, Day 30, and Day 90

Upper extremity activity performance will be assessed using the ARAT. The total score ranges from 0 to 57, with higher scores indicating better upper limb functional ability.

Baseline, Day 30, and Day 90
National Institutes of Health Stroke Scale (NIHSS) Score
Lasso di tempo: Baseline, Day 10, and Day 30

Neurological impairment will be assessed using the NIHSS. Scores range from 0 to 42, with higher scores indicating greater neurological deficit.

Baseline, Day 10, and Day 30
Modified Rankin Scale (mRS) Score
Lasso di tempo: Day 90

Global functional outcome will be assessed using the modified Rankin Scale. Scores range from 0 to 6, with higher scores indicating greater disability.

Day 90
Modified Barthel Index (MBI) Score
Lasso di tempo: Day 30 and Day 90

Activities of daily living will be assessed using the Modified Barthel Index. Higher scores indicate better functional independence.

Day 30 and Day 90

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Training Completion Rate
Lasso di tempo: During the 10-day intervention period

Feasibility outcome defined as the proportion of completed EEG-BCI or sham BCI training sessions among the planned 20 sessions.

During the 10-day intervention period
Effective Training Duration
Lasso di tempo: During the 10-day intervention period

Feasibility outcome defined as the cumulative duration of completed valid BCI training sessions during the intervention period.

During the 10-day intervention period
EEG Signal Quality and BCI Performance Metrics
Lasso di tempo: During the 10-day intervention period

Feasibility outcome assessing EEG acquisition quality and available BCI performance metrics, including signal quality and classification accuracy when available.

During the 10-day intervention period
Follow-up completion rate
Lasso di tempo: Through Day 90

Feasibility outcome defined as the proportion of randomized participants who complete scheduled outcome assessments through Day 90.

Through Day 90
Protocol deviation rate
Lasso di tempo: From randomization through Day 90

Feasibility outcome defined as the proportion of participants with one or more protocol deviations.

From randomization through Day 90
Incidence of symptomatic intracranial hemorrhage
Lasso di tempo: From baseline through Day 90

Safety outcome defined as the occurrence of symptomatic intracranial hemorrhage after randomization.

From baseline through Day 90
Incidence of any intracranial hemorrhage
Lasso di tempo: From baseline through Day 90

Safety outcome defined as the occurrence of any type of intracranial hemorrhage after randomization.

From baseline through Day 90
Incidence of neurological deterioration
Lasso di tempo: From baseline through Day 90

Safety outcome defined as clinically relevant neurological worsening after randomization, such as an increase in NIHSS score of 4 or more points without another clear explanation.

From baseline through Day 90
Incidence of seizures
Lasso di tempo: From baseline through Day 90

Safety outcome defined as the occurrence of seizure events after randomization.

From baseline through Day 90
Incidence of Falls or Injuries
Lasso di tempo: From baseline through Day 90

Safety outcome defined as the occurrence of falls during the study period.

From baseline through Day 90
Incidence of Cardiovascular and Vital Sign Events
Lasso di tempo: From baseline through Day 90

Safety outcome defined as the occurrence of clinically relevant blood pressure instability or cardiac arrhythmia events during the study period.

From baseline through Day 90
Incidence of training-related discomfort
Lasso di tempo: During the 10-day intervention period

Safety outcome defined as the occurrence of training-related discomfort, including fatigue, headache, dizziness, nausea, skin irritation, or other discomfort associated with the intervention.

During the 10-day intervention period
Incidence of serious adverse events
Lasso di tempo: From baseline through Day 90

Safety outcome defined as the occurrence of serious adverse events (SAEs), including death, life-threatening events, hospitalization or prolongation of hospitalization, persistent or significant disability, or other medically important events.

From baseline through Day 90

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: QinJian Sun, MD, Shandong Provincial Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 ottobre 2026

Completamento primario (Stimato)

1 ottobre 2027

Completamento dello studio (Stimato)

1 dicembre 2027

Date di iscrizione allo studio

Primo inviato

29 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 maggio 2026

Primo Inserito (Effettivo)

13 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

25 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi